Company: HQL
Filing Date: 2025-11-26
Form Type: NPORT-P
Source: 0001410368-25-032525
Chunk: 87

Company: abrdn Life Sciences Investors
Filing Date: 2025-11-26
Form: NPORT-P
Chunk 87
---
 |
| e. Maturity date.   |     |

f. Provide the following information concerning the securities subject to the repurchase agreement (i.e., collateral). If multiple securities of an issuer are subject to the repurchase agreement, those securities may be aggregated in responding to Items C.10.f.i-iii.

Item C.11. For derivatives, also provide:

| a. Type of derivative instrument that most closely                  
 represents the investment, selected from among the following        
 (forward, future, option, swaption, swap (including but not limited 
 to total return swaps, credit default swaps, and interest rate      
 swaps), warrant, other).                                            | Other  |
| If "other", provide a brief description.                            | rights |

b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

| Counterparty Record:		1       |     |
| Name of counterparty.         | N/A |
| LEI (if any) of counterparty. | N/A |

3. If the reference instrument is neither a derivative or an index, the description of the reference instrument shall include the name of issuer and title of issue, as well as CUSIP of the reference instrument, ISIN (if CUSIP is not available), ticker if (CUSIP and ISIN are not available), or other identifier (if CUSIP, ISIN, and ticker are not available).

| Name of issuer. | Chinook Therapeutics, Inc. |
| Title of issue. | Chinook Therapeutics, Inc. |

At least one of the following other identifiers:

| Identifier. | CUSIP     |
| CUSIP.      | 16961L106 |

| Identifier.                       | ISIN (if CUSIP is not available) |
| ISIN (if CUSIP is not available). | US16961L1061                     |

| ii.	Termination or maturity (if any).                                                         |           2099-12-31 |
| iii.	Notional amount(s).                                                                      |       59063.00000000 |
| ISO Currency Code.                                                                            | United States Dollar |
| iv.	Delta (if applicable).                                                                    |                 XXXX |
| Unrealized appreciation or depreciation. Depreciation shall be reported as a negative number. |       18900.16000000 |

| For each investment held by the Fund and its consolidated subsidiaries, 
 disclose the information requested in